Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.076|
|52 Week High||AU$0.069|
|52 Week Low||AU$0.15|
|1 Month Change||2.01%|
|3 Month Change||2.70%|
|1 Year Change||-49.33%|
|3 Year Change||-61.03%|
|5 Year Change||-50.97%|
|Change since IPO||-71.85%|
Recent News & Updates
|RGS||AU Biotechs||AU Market|
Return vs Industry: RGS underperformed the Australian Biotechs industry which returned 1.5% over the past year.
Return vs Market: RGS underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: RGS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: RGS's weekly volatility (6%) has been stable over the past year.
About the Company
Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases. Its lead platform technology includes Progenza, a cryopreserved multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing.
Regeneus Fundamentals Summary
|RGS fundamental statistics|
Is RGS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RGS income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.007|
|Net Profit Margin||27.06%|
How did RGS perform over the long term?See historical performance and comparison
Is Regeneus undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RGS (A$0.08) is trading below our estimate of fair value (A$1.32)
Significantly Below Fair Value: RGS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RGS is good value based on its PE Ratio (10.8x) compared to the Global Biotechs industry average (34.4x).
PE vs Market: RGS is good value based on its PE Ratio (10.8x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RGS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RGS is overvalued based on its PB Ratio (9.7x) compared to the AU Biotechs industry average (4.9x).
How is Regeneus forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Regeneus has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Regeneus performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RGS has high quality earnings.
Growing Profit Margin: RGS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: RGS has become profitable over the past 5 years, growing earnings by 5.6% per year.
Accelerating Growth: RGS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RGS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (45.9%).
Return on Equity
High ROE: RGS's Return on Equity (89.3%) is considered outstanding.
How is Regeneus's financial position?
Financial Position Analysis
Short Term Liabilities: RGS's short term assets (A$5.2M) exceed its short term liabilities (A$1.3M).
Long Term Liabilities: RGS's short term assets (A$5.2M) exceed its long term liabilities (A$1.6M).
Debt to Equity History and Analysis
Debt Level: RGS's debt to equity ratio (63.4%) is considered high.
Reducing Debt: Insufficient data to determine if RGS's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: RGS's debt is well covered by operating cash flow (158.3%).
Interest Coverage: RGS's interest payments on its debt are well covered by EBIT (32.4x coverage).
What is Regeneus's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RGS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RGS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RGS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RGS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Karolis Rosickas serves as Chief Executive Officer at Regeneus Ltd since November 2, 2020. He is an experienced executive and healthcare entrepreneur with business experience in healthcare, technology...
Experienced Management: RGS's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Experienced Board: RGS's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.
Regeneus Ltd's employee growth, exchange listings and data sources
- Name: Regeneus Ltd
- Ticker: RGS
- Exchange: ASX
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$23.289m
- Shares outstanding: 306.44m
- Website: https://regeneus.com.au
- Regeneus Ltd
- 2 Paddington Street
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 07:04|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.